Value Reporting Foundation (VRF) / Sustainability Accounting Standards Board (SASB)

Health Care Sector & Biotechnology and Pharmaceuticals Industry

At Novo Nordisk, we strive to adhere to the disclosures of the VRF/ SASB standards that apply to our industry. We do this to demonstrate our commitment to being transparent and accountable for how we operate. We are fully or partially aligned with all the 25 indicators.

Data and information disclosed are sourced from Novo Nordisk's integrated Annual Report / Form 20-F, our ESG Portal and publicly available information at novonordisk.com. Further ESG-related disclosures are available at novonordisk.com, e.g., the Remuneration Report, Corporate Governance Report and CDP report as well as Novo Nordisk's public policies and positions.

Overview of our assessment of Novo Nordisk's alignment with VRF/ SASB

Code	Accounting metric	Novo Nordisk references
Safety of Clinical Trial Participants		
HC-BP-210a.1	Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials	We report on how we ensure quality and patient safety. See the "Patient safety and product quality" section in our ESG Portal. https://www.novonordisk.com/sustainable-business/esg-portal.html
HC-BP-210a.2	Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)	We report on the aggregated total number of failed inspections. Failed inspections are defined as inspections where Warning Letters or EMA non-compliance letters related to GMP inspections are received, GMP/ISO certificates for strategic sites are lost, pre-approval inspections result in a Complete Response Letter, study conclusions are changed due to GCP/GLP inspection issues, or marketing or import authorisations are withdrawn due to inspection issues (note 9.4, p. 95). https://annualreport.novonordisk.com We do not report separately on the number of FDA Sponsor Inspections related to clinical trial management that resulted in VAI and OAI.
HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	We report on material settlements in note 3.5 (p. 69) in the financial statements in our Annual Report. https://annualreport.novonordisk.com
Access to Medicines		
HC-BP-240a.1	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	We report on our actions in the Social performance section in our Annual Report (p. 15-19) and on novonordisk.com. https://annualreport.novonordisk.com https://www.novonordisk.com/sustainable-business/access-and-affordability.html

Code	Accounting metric	Novo Nordisk references
HC-BP-240a.2	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	We report on our products on the WHO List of Prequalified Medicinal Products in the Social performance section in our Annual Report (p. 15-16)
Affordability & Pricing		
HC-BP-240b.1	Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period	We report on material settlements in note 3.5 (p. 69) in the financial statements in our Annual Report. https://annualreport.novonordisk.com
HC-BP-240b.2	Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year	We report on year-on-year average list and average net price changes across our US product portfolio in note 8.6 (p. 93) in our Annual Report. https://annualreport.novonordisk.com
HC-BP-240b.3	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year	We report on year-on-year average list and average net price changes across our US insulin portfolio in note 8.6 (p. 93) in our Annual Report. https://annualreport.novonordisk.com
Drug Safety		
HC-BP-250a.1	List of products listed in the Food and Drug Administration's (FDA) MedWatch Safety Alerts for Human Medical Products database	The data is publicly available at the US FDA website. In 2018, Novo Nordisk had one product listed in the FDA's MedWatch Safety Alerts, Cartridge holders in certain NovoPen Echo® Insulin Delivery Devices. We disclose all product recalls in our Annual Report (note 9.3, p. 91) and on novonordisk.com. https://annualreport.novonordisk.com https://www.novonordisk.com/news-and-media/news-and-ir-materials.html
HC-BP-250a.2	Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System	We report to the US FDA Adverse Event Reporting and the EU's EudraVigilance systems.
HC-BP-250a.3	Number of recalls issued, total units recalled	We disclose the number of recalls issued in our Annual Report (note 9.3, p. 94). Whenever there are instances of recalls, local health authorities are informed to ensure that distributors, pharmacies, doctors and patients received appropriate information, if applicable. https://annualreport.novonordisk.com https://www.novonordisk.com/news-and-media/news-and-ir-materials.html

Code	Accounting metric	Novo Nordisk references
HC-BP-250a.4	Total amount of product accepted for takeback, reuse, or disposal	In 2020, Novo Nordisk initiated the "Take-back Programme" in order to address the end-of-life challenge. Initially, we focused on disposable devices with a pilot project in Denmark, which showed that it was possible to reclaim and reuse the plastic that makes up three-quarters of these devices. In 2022 we rolled out pen recycling pilots in the U.K., France and Brazil. Read more in the Environmental section of our Annual Report (p. 14) and at novonordisk.com. https://annualreport.novonordisk.com https://www.novonordisk.com/sustainable-business/zero-environmental-impact.html
HC-BP-250a.5	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	We report on the aggregated total number of failed inspections. Failed inspections are defined as inspections where Warning Letters or EMA non-compliance letters related to GMP inspections are received, GMP/ISO certificates for strategic sites are lost, pre-approval inspections result in a Complete Response Letter, study conclusions are changed due to GCP/GLP inspection issues, or marketing or import authorisations are withdrawn due to inspection issues (note 9.4, p. 95). https://annualreport.novonordisk.com We do not report separately on the number of FDA Sponsor Inspections related to clinical trial management that resulted in VAI and OAI.
Counterfeit Drugs		
HC-BP-260a.1	Description of methods used to maintain traceability of products throughout the supply chain & prevent counterfeiting	We have been implementing a comprehensive anti-counterfeit programm to ensure patient safety. A cross functional Anti-Counterfeit Working Group, chaired by the head of our Customer Complaint Centre, ensures vigilant risk assessment and implementation of an Anti-Counterfeit Product strategy. We have an ongoing international collaboration with regulatory bodies, scientific and trade organisations, law enforcement agencies and other stakeholders to investigate counterfeit products and to influence legislation regarding new anti-counterfeit measures. We are a member of the Pharmaceutical Security Institute (PSI), which on behalf of the approximately 30 largest pharmaceutical companies, collects information and coordinates investigations into counterfeit products worldwide. Please find further information on our ESG Portal in the "Patient safety and product quality" section. https://www.novonordisk.com/sustainable-business/esg-portal.html

Code	Accounting metric	Novo Nordisk references
HC-BP-260a.2	Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products	We conduct regular reviews of risks through information exchange with external collaborators. The investigation of suspected counterfeit cases is reported via our affiliates or authorities. Monthly internal counterfeit surveillance reports are reviewed by key specialists and management. Our Quality Management System identifies and investigates alleged occurrences of counterfeited Novo Nordisk products. In China, we work with local investigation firms to perform market searches to help health authorities track down and seize counterfeit products. Outside of China, we conduct investigations of suspected counterfeit products based on risk analysis and take legal action against those involved in the counterfeiting of our products. Please find further information on our ESG Portal in the "Patient safety and product quality" section. https://www.novonordisk.com/sustainable-business/esg-portal.html
HC-BP-260a.3	Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products	We report to the Pharmaceutical Security Institute (“PSI”) of which we are a member. The PSI is a not-for-profit organisation dedicated to protecting public health, sharing information on the counterfeiting of pharmaceuticals and initiating enforcement actions through the appropriate authorities. Further information can be found on our ESG Portal in the "Patient safety and product quality" section. PSI are producing an annual rapport on all reported counterfeit cases and developments over time. https://www.novonordisk.com/sustainable-business/esg-portal.html
Ethical Marketing		
HC-BP-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	We have included a description of our approach to marketing in our Business Ethics Code of Conduct. https://www.novonordisk.com/content/dam/nncorp/global/en/sustainablebusiness/pdfs/novo-nordisk-business-ethics-code-of-conduct.pdf We disclose the type and number of false marketing claims, and report on material settlements in the financial statements in our Annual Report (note 3.5, p. 69). https://annualreport.novonordisk.com
Employee Recruitment, Development & Retention		

Code	Accounting metric	Novo Nordisk references
HC-BP-330a.2	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others	We report on turnover in our Annual Report (note 8.2, p. 92). https://annualreport.novonordisk.com/
Supply Chain Management		
HC-BP-430a.1	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third party audit programs for integrity of supply chain and ingredients	We report in note 9.2 (p.94) of our Annual Report that we conduct supplier audits internally and do not participate in third party audit programs.In addition, we commission external service providers from time to time to undertake quality-focused audits of our supply chain. Any findings are dealt with according to our internal audit process procedures.All our production facilities are certified according to ISO 14001, environmental management. The ISO 14001 certified Environmental Management system ensures continuous improvements through a systematic approach. The production of active pharmaceutical ingredients (“API”) in Kalundborg, Denmark, is also certified according to ISO 50001, energy management.https://www.novonordisk.com/sustainable-business/zero-environmental-impact/environmental-policy.html
Business Ethics		
HC-BP-510a.1	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	We report on material settlements in note 3.5 (p. 69) in the financial statements in our Annual Report. https://annualreport.novonordisk.com
Activity metrics		
HC-BP-000.A	Number of patients treated	We report on total number of patients treated in our Annual Report in note 8.5 (p. 92). https://annualreport.novonordisk.com
HC-BP-000.B	Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)	We report on number of drugs in our marketed portfolio and in R&D development in our Annual Report via our pipeline (p. 29) and product (p. 101) overviews. https://annualreport.novonordisk.com